Frederick Mihm, M.D.

Publication Details

  • EFFECTS OF ANTI-C5A ANTIBODIES ON THE ADULT RESPIRATORY-DISTRESS SYNDROME IN SEPTIC PRIMATES JOURNAL OF CLINICAL INVESTIGATION Stevens, J. H., OHANLEY, P., Shapiro, J. M., Mihm, F. G., Satoh, P. S., Collins, J. A., Raffin, T. A. 1986; 77 (6): 1812-1816

    Abstract:

    In vitro and in vivo studies have suggested that human complement component C5a plays a key role in neutrophil injury in the adult respiratory distress syndrome (ARDS). First, using leukocyte aggregometry, we demonstrated that the addition of a recently developed rabbit anti-human polyclonal antibody to C5a des arg to endotoxin-activated plasma prevented leukocyte aggregation in vitro. We then administered the anti-C5a des arg antibody to septic primates (Macaca fascicularis). Three groups of primates, control, septic, and anti-C5a antibody treated septic, were studied (n = 4 in each group). A 30-min infusion of Escherichia coli (1 X 10(10)/kg) resulted in severe sepsis and ARDS. Primates were killed 4 h after completion of the E. coli infusion. Septic animals not treated with anti-C5a antibody had 75% mortality (3/4), decreased oxygenation, severe pulmonary edema, and profound hypotension. Septic primates treated with anti-C5a antibodies did not die and did not develop decreased oxygenation (P less than 0.05) or increased extravascular lung water (P less than 0.05). They also had a marked recovery in their mean arterial blood pressure (P less than 0.05). This study demonstrates that treatment with rabbit anti-human C5a des arg antibodies attenuates ARDS and some of the systemic manifestations of sepsis in nonhuman primates.

    View details for Web of Science ID A1986C512700014

    View details for PubMedID 3711336

Stanford Medicine Resources:

Footer Links: